Meet Medicilon at CABS 2022 BioPacific Conference! It kicks off on November 12, 2022 in San Mateo. This year’s conference will showcase success stories and best practices for innovation and improving the resilience of organizations. Maybe Medicilon can help you solve your current problem and become a partner of choice! Dr. Xuedong Dai, EVP of Medicilon International R&D Service Department, will lead the Medicilon American team on the site. Looking forward to seeing you at booth 16!
About CABS 2022 BioPacific Conference
Chinese American Biopharmaceutical Society (CABS) is a non-profit professional association of biomedicine. As the largest and most active Chinese biomedical association in North America, and the unique condition of being in the first important town of biomedicine, CABS extensively promotes exchanges in the fields of life sciences between China and the United States. While everyday life is starting to normalize in many parts of the world despite ongoing COVID-19, economic and supply chain turbulences present both new challenges and opportunities for the life science and biopharmaceutical industries. This year’s conference will showcase success stories and best practices for innovation and improving the resilience of organizations.
Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance. Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.
Medicilon Drug Discovery Services
Medicilon Drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. In terms of chemistry, it can undertake multi-dimensional business such as custom synthesis, compound library construction, SAR compound synthesis and screening, compound structure and biological activity optimization.
The medicinal chemistry team deeply cross-integrates chemistry and biology into each project, and flexibly uses the powerful expertise of computational chemistry to aid the compound design process. At the same time, Medicilon extensively uses advanced drug discovery technology, including PROTAC targeted protein degradation technology, DEL DNA-encoded small molecule compound library screening technology, ADC antibody drug conjugation technology, etc. Medicilon efficiently promotes customers' drug research and development projects, controls costs, and improves quality!
Innovative Drug R&D Services
Medicilon offers clients with a pool of payload drugs of various mechanisms and offers custom synthesis of payload drugs. Medicilon fully understands the complexity of ADA evaluation and offers our clients with comprehensive immunogenicity assays.
Proteolysis Targeting Chimera (PROTAC)
Medicilon gathers the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition of established a linker library containing hundreds of linking molecules. Medicilon has established a complete PROTAC in vitro analysis platform.
mRNA Vaccine Bioanalysis Platform
Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines, specifically the research of LNP-mRNA drugs and vaccines. We have accumulated rich experience on this technology; therefore, we establish the bioanalysis platform for mRNA vaccines. Based on the mechanism and characteristics of mRNA vaccines, Medicilon’s Bioanalysis Department has established an evaluation platform covering metabolism and biodistribution, key sequence domain antibodies and antiviral neutralizing antibody titers and the evaluation of effectiveness of cellular immune response.
As the first CRO stock on the Sci-tech Innovation Board, Medicilon is one of the companies that pay attention to AI technology in the industry at the beginning. Currently, Medicilon uses deep neural network machine learning technology to construct a BTK inhibitor drug design model. Medicilon also commits to establishing a molecular design and screening platform for BTK inhibitor drugs, launching “CRO+AI” to accelerate the development of new drugs.
Share：
Online registrationRelevant
news
marketing@medicilon.com
